Abstract
The neuropeptide substance P (SP) has been supposed to be involved in the etiopathology of affective disorders, mainly because of the finding of increased levels of SP in the cerebrospinal fluid of depressed patients and the preliminary evidence of antidepressant effects of SP-receptor antagonists in depressed patients. We investigated whether SP may induce changes of sleep, mood and neuroendocrine measures that are similar to those in depressed patients. In a double-blind, randomized cross-over design, 12 healthy young men were investigated in two blocks of three consecutive nights, in which SP or NaCl was intravenously infused during the third night. Polysomnographic recordings were obtained during all nights and blood samples were drawn every 30 min during the third night. Infusion of SP caused a significant worsening of the mood of the subjects, led to an increase of REM latency and time awake during the SP-infusion intervals, caused increased stage 1 sleep in the first part of the night, and led to increased cortisol and thyroid stimulating hormone levels and a trend for decreased growth hormone levels. These effects can be interpreted as evidence for a central arousing effect of SP. Further studies should focus on the effects of substance P in patients with depressive or other psychiatric disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Berger M, Riemann D . (1993): Normal and abnormal REM sleep regulation: REM sleep in depression-an overview. J Sleep Res 2: 211–223
Born J, Spath-Schwalbe E, Schwakenhofer H, Kern W, Fehm HL . (1989): Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on sleep in normal man. J Clin Endocrinol Metab 68: 904–911
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ . (1989): The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193–213
Coiro V, Capretti L, Volpi R, Davoli C, Marcato A, Cavazzini U, Caffarri G, Rossi G, Chiodera P . (1992a): Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate. Neuroendocrinology 56: 459–463
Coiro V, Volpi R, Capretti L, Speroni G, Bocchi R, Caffarri G, Colla R, Rossi G, Chiodera P . (1992b): Intravenously infused substance P enhances basal and growth hormone (GH) releasing hormone-stimulated GH secretion in normal men. Peptides 13: 843–846
File SE . (2000): NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl) 152: 105–109
Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L . (2001): 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21: 8188–8197
Görtelmeyer R . (1981): On the development of a standardized sleep inventory for the assessment of sleep. In Kubicki S and Herrmann WM (eds), Methods of Sleep Research. Stuttgart, Germany, Gustav Fischer, pp 93–98
Holsboer F . (1995) Neuroendocrinology of mood disorders. Psychopharmacology 957–970
Holsboer F, von Bardeleben U, Steiger A . (1988): Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology 48: 32–38
Jarrett DB, Miewald JM, Kupfer DJ . (1990): Recurrent depression is associated with a persistent reduction in sleep-related growth hormone secretion. Arch Gen Psychiatry 47: 113–118
Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Rupniak NM . (1998): Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640–1645
Lauer C, Riemann D, Lund R, Berger M . (1987): Shortened REM latency: a consequence of psychological strain? Psychophysiology 24: 263–271
Linkowski P, Mendlewicz J, Kerkhofs M, Leclercq R, Golstein J, Brasseur M, Copinschi G, Van Cauter E . (1987): 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab 65: 141–152
Otsuka M, Yoshioka K . (1993): Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73: 229–308
Papp M, Vassout A, Gentsch C . (2000): The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115: 19–23
Pioro EP . (1990): Distribution of substance P and enkephalin immunoreactive neurons and fibers. In Paxinos G (ed), The Human Nervous System. San Diego, New York, Academic Press, pp 1051–1094
Quartara L, Maggi CA . (1998): The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 32: 1–49
Rechtschaffen A, Kales A . (1986): A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington D.C., US Government Printing Office
Riemann D, Berger M, Voderholzer U . (2001): Sleep and depression - results from psychobiological studies: An overview. Biol Psychol 57: 67–103
Rupniak NM, Kramer MS . (1999): Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20: 485–490
Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ . (2001): Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98: 1912–1917
Schaffalitzky De Muckadell OB, Aggestrup S, Stentoft P . (1986): Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol 21: 498–502
Schedlowski M, Fluge T, Richter S, Tewes U, Schmidt RE, Wagner TO . (1995): Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 20: 103–110
Sergeyev V, Hokfelt T, Hurd Y . (1999): Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 10: 3967–3970
Steiger A, Holsboer F . (1997): Neuropeptides and human sleep. Sleep 20: 1038–1052
Steiger A, von Bardeleben U, Guldner J, Lauer C, Rothe B, Holsboer F . (1993): The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry 17: 125–137
Stout SC, Owens MJ, Nemeroff CB . (2001) Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 41: 877–906
Voderholzer U, Laakmann G, Wittmann R, Daffner-Bujia C, Hinz A, Haag C, Baghai T . (1993): Profiles of spontaneous 24-hour and stimulated growth hormone secretion in male patients with endogenous depression. Psychiatry Res 47: 215–227
von Zerssen D . (1986): Clinical Self-rating scales (CSRS) of the Munich Psychiatry Information System (PSYCHIS München) In Sartorius N Ban T (eds.), Assessment of Depression. Berlin, New York, Springer-Verlag, pp 270–303
Weiss DW, Hirt R, Tarcic N, Berzon Y, Ben-Zur H, Breznitz S, Glaser B, Grover NB, Baras M, O′Dorisio TM . (1996): Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 22: 5–14
Acknowledgements
We would like to thank Dr. Gesa Weske for her help in subject's care and data analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lieb, K., Ahlvers, K., Dancker, K. et al. Effects of the Neuropeptide Substance P on Sleep, Mood, and Neuroendocrine Measures in Healthy Young Men. Neuropsychopharmacol 27, 1041–1049 (2002). https://doi.org/10.1016/S0893-133X(02)00369-X
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(02)00369-X
Keywords
This article is cited by
-
Relationship with excessive daytime sleepiness and serum substance P levels in OSAS patients and the effect of PAP treatment
Sleep and Biological Rhythms (2019)
-
Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co-morbidities
Neurochemical Research (2019)
-
Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain
BMC Neuroscience (2007)
